Первичный гиперпаратиреоз.
Эпидемиология, клиника, современные принципы диагностики и лечения
Диссертация
Основные положения диссертации доложены и обсуждены на Ученом совете ФГУ ЭНЦ Росмедтехнологий 10.10.2009, на межотделенческих научных конференциях ФГУ ЭНЦ, на заседаниях Московского общества эндокринологов посвященных вопросам ПГПТ, в рамках Совещания по вопросам эпидемиологии ПГПТ представлены результаты базы данных ЭНЦ по ПГПТ в г. Москва (2009,2010гг., Москва), на Муеждународном Форуме… Читать ещё >
Содержание
- Список сокращений
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Эпидемиология, этиология и классификация первичного гиперпаратиреоза (ПГПТ)
- 1. 1. 1. Общая эпидемиология
- 1. 1. 2. Эпидемиология мягкой формы
- 1. 1. 3. Этиология
- 1. 2. Клиническая картина и патогенез первичного гиперпаратиреоза
- 1. 2. 1. Состояние костной ткани
- 1. 2. 2. Состояние почек
- 1. 2. 3. Состояние сердечно-сосудистой системы
- 1. 2. 4. Состояние жирового и углеводного обмена
- 1. 2. 5. Состояние пуринового обмена
- 1. 2. 6. Другие клинические проявление первичного гиперпаратиреоза. Гиперкальцический криз
- 1. 2. 7. Нормокальциемический вариант ПГПТ
- 1. 3. Диагностика первичного гиперпаратиреоза
- 1. 3. 1. Лабораторные методы исследования
- 1. 3. 2. Инструментальные методы исследования
- 1. 3. 3. Топическая диагностика
- 1. 4. Лечение первичного гиперпаратиреоза
- 1. 4. 1. Хирургическое лечение
- 1. 4. 2. Консервативное лечение
- 1. 4. 2. 1. Использование антирезорбтивной терапии
- 1. 4. 2. 2. Использование кальцимиметиков
- 1. 4. 2. 3. Оценка наиболее выгодной стратегии лечения асимптомного первичного гиперпаратиреоза с экономической точки зрения
- 3. 2. 5. 5. Результаты исследования показателей костного метаболизма
- 3. 2. 5. 6. Оценка уровня 250НД у пациентов с ПГПТ в сравнении с группой контроля и его роли в формировании костных нарушений
- 3. 2. 6. Висцеральные нарушения при первичном гиперпаратиреозе
- 3. 2. 6. 1. Состояние почек
- 3. 2. 6. 2. Нефролитиаз при ПГПТ
- 3. 2. 6. 3. Фильтрационная функция почек на фоне ПГПТ
- 3. 2. 6. 3. 1. Корректная оценка фильтрационной функции почек при ПГПТ
- 3. 2. 6. 3. 2. Связь состояния фильтрационной функции почек и основных показателей ПГПТ
- 3. 2. 6. 4. Инфекция мочевыводящих путей при ПГПТ
- 3. 2. 8. Состояние метаболических процессов на фоне ПГПТ
- 3. 2. 8. 1. Динамика массы тела на фоне ПГПТ
- 3. 2. 8. 2. Состояние липидного спектра крови
- 3. 2. 8. 3. Состояние углеводного обмена
- 3. 2. 8. 4. Состояние пуринового обмена на фоне ПГПТ
- 1. 1. Эпидемиология, этиология и классификация первичного гиперпаратиреоза (ПГПТ)
- 3. 3. Диффернциальная диагностика
- 3. 3. 1. Дифференциальная диагностика нормокальциемической формы гиперпаратиреоза
- 3. 4. Лечение
- 3. 4. 1. Результаты хирургического лечения первичного гиперпаратиреоза
- 3. 4. 1. 1. Результаты морфологического исследования послеоперационного материала
- 3. 4. 1. 2. Оценка эффективности хирургического лечения ПГПТ
- 3. 4. 1. 3. Динамика показателей фосфорно-кальциевого обмена и клинических проявлений на фоне ремиссии ПГПТ после хирургического лечения
- 3. 4. 1. 4. Динамика состояния костной ткани после хирургического лечения в зависимости от степени тяжести ПГПТ
- 3. 4. 1. 5. Проспективное исследование состояния почек после хирургического лечения ПГПТ
- 3. 4. 1. 6. Динамика фильтрационной функции почек после хирургического лечения первичного гиперпаратиреоза
- 3. 4. 1. 6. 1. Динамика фильтрационной функции почек после хирургического лечения у пациентов с исходной ХБП 3−5 стадии
- 3. 4. 1. 6. 2. Динамика фильтрационной функции почек после хирургического лечения у пациентов без ХПН
- 3. 4. 1. Результаты хирургического лечения первичного гиперпаратиреоза
- 3. 5. 1. Результаты сравнительного проспективного исследования эффективности и безопасности консервативного лечения пациенток с ПГПТ в менопаузе
- 3. 5. 1. 1. Динамика гормонально-биохимических показателей
- 3. 5. 1. 2. Изменения МПК
- 3. 5. 1. 3. Динамики показателей жирового обмена
- 3. 5. 1. 4. Динамика состояния ССС
Список литературы
- Беневоленская Л.И. и др. Остеопороз: диагностика, профилактика и лечение. Клинические рекомендации//"ГЭОТАР-Медиа"-М.- 2009.-С.270.
- Вильям М. Кеттайл, Рональд А. Арки //Патофизиология эндокринной системы//М., 2009. С. 145−151.
- Внутренние болезни по Тинсли Р. Харрисону // Практика Москва, 2005.
- Голохвастов H.H., Рыбаков Г. В. Значение гормональных и биохимических нарушений при первичном гиперпаратиреозе в определении характера морфологических изменений околощитовидных желез до операции // Хирургия эндокринных желез. СПб.1995- 49−51.
- Дедов И.И., Мельниченко Г. А., Пронин B.C. и др. // Клиника и диагностика эндокринных нарушений М.: 2005.- 99−111.
- Евменова Т.Д., Шахворост Н. П. Первичный гиперпаратиреоз // Современные аспекты хирургической эндокринологии. Челябинск, 2000- 192−193.
- Майоров М.Ю. Состояние инсулинорезистентности в эволюции сахарного диабета 2 типа. Дисс. .докт.мед.наук — М.-2009.-С.242
- Печерская Г. А., Ишенин Ю. М. Диагностические аспекты первичного гиперпаратиреоза // Казанский медицинский журнал. 2000- 3: 226−227
- Рожинская Л.Я. Остеопенический синдром, при заболеваниях эндокринной системы и постменопаузальный остеопороз (патогенетические аспекты, диагностика и лечение):Дис. .докт.мед.наук -М.- 2001.-С.318.
- Ремизов О.В. Инсулинорезистентность у детей. Гормонально-метаболические аспекты патогенеза, профилактика и лечение СД 2 типа.
- Автореферат дис. .докт.мед.наук -М.- 2005- С. 45.
- AACE/AAES position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005- 11:49−54.
- Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. // J Bone Miner Res. 2002−17(Suppl 2):N18-N23.
- Agarwal A et al, Hyperparathyroidism and malnutrition with severe vitamin D deficiency. // World J Surg. 2009 Nov-33(l 1):2303−13.
- Almqvist EG, Bondeson AG, Bondeson L, et al. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy // Surgery -2002−132:1126−1132.
- Altura RM et al. Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden death ischemic heart disease and hypertaensive vascular diseases. // Artery 1981- 9: 212−231.
- Anderson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease a review. // Europ Heart J. — 2004-Vol25, N20, 1776−1787
- Aurigemma GP, Devereux RB, Wachtell K, et al. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. // Am J Hypertens. -2003−16:180−186.
- Baczynski R, Massry SG, Kohan R, et al. Effect of parathyroid hormone on myocardial energy metabolism in the rat Kidney Int 1985−27:718−725.
- Bannon MP et al. The relationship between primary hyperparathyroidism and diabetes mellitus // Annals of Surgery. 1988, 207: 430−433.
- Bauwens F.R., Duprez D.A., De Buyzere M.L., et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. // Am J Cardiol. 1991 — Vol. 68 — P. 925 929.
- Bilezikian JP, Brandi ML, Rubin M & Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. // Journal of Internal Medicine. 2005, 257 6−17.
- Bilezikian JP, Potts JT, Fuleihan GE-H, et al. Summary statement from a workshop on asymptomatic primary hyperthyroidism: a perspective for the 21st century. // J Clin Endocrinol Metab. 2002−87:5353−5361.
- Bilezikian J., Khan A., Potts J. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. // J Clin Endocrinol Metab. 2009, 94(2): 335 339.
- Bilezikian JP, Silverberg S J. Normocalcemic primary hyperparathyroidism. // Arq Bras Endocrinol Metabol. 2010 Mar-54(2): 106−9.
- Bilezican J., Shonni J. and Silverberg M. Asymptomatic primary hyperparathyroidism. // New England J of Medicine 2004 — Vol. 350 — P. 1746−51.
- Bogin E, Levi J, Harary I, et al. Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria. // Miner Electrolyte Metab. -1982−7:151−156.
- Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. // J Clin Invest. 1981−67:1215−1227.
- Bolland MJ. et al. Association between primary hyperparathyroidism and increased body weight: a meta-analysis.//.! Clin Endocrinology & Methabolism. -2005, 90 (3):1525−1530.
- Bolland MJ et al. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. // Bone. 2006, 38(3): 317−321.
- Bonora E et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study // Diabetes. 1998, 47: 1643−1649.
- Carling T., Rastad J., Szabo E. et al. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism // J. Clin. Endocrinol. Metab. 2000.-Vol. 85. — P. 20 002 003.
- Carling T., Szabo E., Bai M. et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor // J. Clin. Endocrinol. Metab. 2000. — Vol. 85, P. 2042−2047.
- Caufriez A. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. // Ann.Endocrinol. Paris, 2007- 68:241−50.
- Chan WB, Li JK, Chan NN, Chan MH, Ko GT et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. //J Clin.Endocrinol.Metab. 2003−88:581−7.
- Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. // Ann.Surg. 1995−222:402−12.
- Chang CJ, Chen SA, Tai CT, et al. Ventricular tachycardia in a patient with primary hyperparathyroidism. // Pacing Clin Electrophysiol. 2000- 23: 534 537.
- Cheung PS et al. Effect of hyperparathyroidism on the control of diabetes mellitus. // Surgery. 1986, 100: 1039−1047.
- Chou F.F., Sheen-Chen S.M., Leong C.P. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. // Surgery. 1995- 117:18.
- Christensson T and Einarsson K. Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism. // Clinica Chemica Acta. 1977, 78: 411−415.
- Cope O, Culver Pj, Mixter Cg Jr, Nardi Gl. Pancreatitis, a diagnostic clue to hyperparathyroidism. // Ann Surg. 1957 Jun-145(6):857−63.
- Croce C.G., Borretta V., Gianotti L, Cesario F, Baffoni C., Emmolo I., Pellegrino M., Borretta G. Renal function in primary hyperparathyroidism.
- Parathyroids 2010: from patophysiology to the clinical use of PTH. Pisa, February 11−13,2010.
- Curione M, et al. Increased risk of cardiac death in primary hyperparathyroidism: what is a role of electrical instability. Int J Cardiol. 2007 l-121(2):200−2.
- De Geronimo S, Romagnoli E, Diacinti D, D’Erasmo E, Minisola S The risk of fractures in postmenopausal women with primary hyperparathyroidism. // European Journal of Endocrinology. 2006 — Vol 155, Issue 3- pp. — 415−20.
- De la Torre NG et al. Parathyroid adenomas and cardiovascular risk. // Endocrine-related cancer 2003, 10: 309−322.
- DeFronzo RA and Lang R. Hypophosphatemia and glucoseintolerance: evidence for tissue insensitivity to insulin. // New England J of Medicine. -1980,303: 1259−1263.
- Delfini E, Petramala L. et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. // Metabolism. 2007, 56(1): 3036.
- Demers C, Rouleau JL, Leung TK, Tardif JC. Hypercalcemic cardiomyopathy primary obstructive hypertrophic cardiomyopathy. // Can J Cardiol. 1998- 14(11): 1397−1400.
- Dempster DW, Caldwell NJ, Goldstein SA, et al (2002) Three dimensional assessment of trabecular architecture in mild primary hyperparathyroidism. // J Bone Miner Res 17 Suppl 1.: 1173a.
- Dempster DW, Parisien M, Silverberg SJ, et al. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. // J Clin Endocrinol Metab. 1999 May-84(5): 1562−6.
- Dominiczak AF, Lyall F, Morton JJ, et al. Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. // Clin Sci -1990−78:127−132.
- Dorheim MA et al. Osteoblastic gene expression during adipogenesis in hematopoetic supporting murine bone marrow stromal cells. // J Cell Physiol 1993, 154:317−328.
- Egbuna O, Brown E Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. // Best Pract Res Clin Rheumatol. 2008 -22(1)-pp. 129−48.
- Erem C et al. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-dimer levels // Exp Cin Endocrinol Diabetes. 2008, 16: 324−330.
- Falchetti A, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. GeneReviews Internet. Seattle (WA): University of Washington, Seattle- 1993-.2005 Aug 31 [updated 2010 Mar 2].
- Fardella C & Rodriguez-Portales JA. Intracellular calcium and blood pressure: comparison between primary hyperparathyroidism and essential hypertension. // Journal of Endocrinological Investigation 1995- 18: 827−832.
- Geelhoed G.W., Kelly T.R. Pseudogout as a clue and complication in primary hyperparathyroidism. // Surgery. 1989 Dec- 106(6): 1036−42.
- Geerdink EA, Van der Luijt RB, Lips CJ Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? // Eur J Endocrinol. 2003 Dec-149(6):577−82.
- Gennari C, Nami R, Gonneli S. Hypertension in primary hyperparathyroidism: the role of adrenergic and rennin-angiotensin-aldosterone systems. // Mineral and Electrolyte Metabolism. 1995- 21: 77−81.
- Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. // Ann Intern Med. 1992−117:831−836.
- Grey A.B., Evans M.C., Stapleton J.P., et al. Body weight and bone mineral density in postmenopausal- women with primary hyperparathyroidism. // Ann Intern Med. 1994- 121:745.
- Grey A and Reid I. Body weight and bone mineral density in hyperparathyroidism. // Ann Intern Med. 1995, 123: 732.
- Grey A.B., Stapleton J.P., Evans M.C., et al. Accelerated bone loss in postmenopausal women with mild primary hyperparathyroidism. // Clin Endocrinol. 1996- 44:697.
- Guo C.Y., Thomas W.E., A.W. al-Dehaimi, A.M. Assiri, and R Eastell, Longitudinal chenges in bone mineral density and bone turnover in postmenopausal women with primary hyperperethyroidism. // J. Clin. Endocrinol. Metab. 1996 81: 3487−3491.
- Haap M. et al. Association of serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in non-diabetic subjects. // Eur J Clin Nutr. 2006, 60(6): 734−739.
- Haber R.S. et al. Ultrasonography for preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism: comparison with (99m)technetium sestamibi scintigraphy. // Clin, endocrinol. (Oxf.) 2002 -Aug. 57 (2).
- Hagstroem E et al. Normalized dyslipidemia after parathyroidectomy in mild primary hyperparathyroidism: population based study over five years. // Clin Endocrinol. 2002, 56(2): 253−260.
- Hagstroem E et al. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. // European J of Endocrinology. 2006, 155: 33−39.
- Hagstroem E et al. Serum calcium is independently associated with insulin sensitivity measured with euglycemic-hyperinsulinaemic clamp in community-based cohort // Diabetologia. 2007, 50 (2): 317−324.
- Hamdy NA, Gray RD, McCloskey E, Galloway J, Rattenbury JM, Brown CB, Kanis JA 1987 Clodronate in the medical management of hyperparathyroidism. // Bone. (Suppl 1):S69-S77.
- Hampi H, Sternberg C, Berweck S, et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. // Clin Nephrol. 2002- 58, Suppl 1: 73−96.
- Harnett JD, Parfrey PS, Griffiths SM, et al. Left ventricular hypertrophy in end-stage renal disease. //Nephron. 1988- 48(2): 107−15.
- Hedback G, Oden A. Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Invest 1998 -28 — pp. 1011−1018.
- Hedback GM, Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. // J Intern Med. 2002 — 25:476−483.
- Hedback G, Oden A, Tisell LE. The influence of surgery on the risk of death in patients with primary hyperparathyroidism. // World J Surg. 199 115:399— 405- discussion 406−407.
- Hedback G., Oden A. Increased risk of death from PHPT—an update. // Eur J Clin Invest. 1998 — Vol. 28- P. 271−276.
- Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A. Premature death in patients operated on for primary hyperparathyroidism. // World J Surg. 1990 14:829−835- discussion 836.
- Hisatome I, Ishimura M, Sasaki N et al. Renal handling of urate in two patients with hyperuricemia and primary hyperparathyroidism. // Intern Med. 1992 Jun.-31(6): 807−811.
- Hui Y, Hao’Y, Chen X, et al. Relationship between some humoral factors and left ventricular hypertrophy in essential hypertension. // Chin Med J. -1996−109:885−887.
- Hvarfer A et al. Interactions between indices of calcium methabolism and blood pressure during calcium infusion in humans. // J of Human Hypertension. 1989- 3: 211−220.
- Ikeo Y, Sakurai A, Hashizume K. Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies. // Jpn J Cancer Res. 1999 -0ct-90(10): 1088−95.
- Jones AC, Chuck AJ, Arie EA et al. Diseases associated with calcium pyrophosphate deposition disease. // Semin Arthritis Rheum. 1992 Dec- 22(3): 188−202.
- Jorde, R., Bonaa, K.H. & Sundsfjord, J. (2000) Primary hyperparathyroidism detected in a health screening. The Tromso study. // Journal of Clinical Epidemiology. 53, 1164−1169.
- Kashitani T, Makino H, Nagake Y et al. Two cases of hypercalcemic nephropathy associated with primary hyperparathyroidism. // Nippon Jinzo Gakkai Shi. 1993 — 35(10)-pp. 1189−94.
- Kautzky-Wilier A et al. Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery. // Clinical Endocrinology. 1992, 37: 147−155.
- Kearney P, Reardon M, O’Hare J. Primary hyperparathyroidism presenting as torsade de pointes. // Br Heart J. 1993- 70: 473.
- Khan A.A., Bilezikian J. P, et al. The Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism. // J. Clin. Endocrin. Metab. -2009−94 (2): 333−334.
- Khan- A, Bilezikian J, Kung A et al. Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial. // J Clin.Endocrinol.Metab. 2004 — 89(7) — PP.3319−25.
- Khosla S, Melton LJ 3rd, Wermers RA, et al (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. // J Bone Miner Res 14:1700−1707.
- Knaheli AA et al. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. // Diabetes Metab Res Rev. 2007, 23(1): 43−48.
- Kosch M, Hausberg M, Vormbrock K, et al. Studies on flow-mediated vasodilation and intima-media thickness of the brachial" artery in patients with primary hyperparathyroidism. // Am J Hypertens. 2000−13:759−764.
- Kosch M, Hausberg M, Vormbrock K, et al. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. // Cardiovasc Res. -2000−47:813−818.
- Kotova LN, Goloshchanov OA, Kassovich NG, Kondakova SP, Kulagina SV. Difficulties in the diagnosis of primary and secondary hyperparathyroidism. // Klin Med. Moscow 1991 Oct-69(lQ):85−6.
- Krauss RM. Atherogenicity of triglyceride rich lipoproteins. // American J of cardiology. 1998, 81:13B-17B.
- Kushner D. Calcium and the Kidney. // The American Journal of Clinical Nutrition. 2006 vol. 4 N.5 — PP. 561−579.
- Kushner D Calcium and the kidney. // Am J Clin Nutrition. 1986- 4 (5) — PP. 561−679.
- Kumar S et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. // Clinical Endocrinology. 1994, 40: 47−53.
- Marx S.J. Hyprparathyroid and Hypoparathyroid Disorders. // N. Engl J Med. -2000.343:1863−1875.
- McCarty MF. Nutritional modulation of parathyroid hormone secretion may influence risk for left ventricular hypertrophy. // Med Hypotheses. 2005- 64(5): 1015−2.
- McCarty MF and Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. // Med Hypotheses. 2003, 61:535−542.
- Melton LJ 3rd. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965−1992. // Ann Intern Med. 1997 Mar 15−126(6):433−40.
- Mollerup CL, Vestergaard P, Frakjaer VG, Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. // BMJ. 2002 Oct 12−325(7368):807.
- Mollerup C.L. and Lindewald H. Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. // World J.Surg. 1999 V. 23, № 2. P. 173−176 (307).
- Morfis L, Smerdely P, Howes LGRelationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. // J Hypertens. 1997. — Nov- 15(11): 1271 -6.
- Nainby-Luxmoore J.C., Langford H.G., Nelson N.C., Watson RLet al. A case-comparison study of hypertension and hyperparathyroidism. // J Clin Endocrinol Metab. 1982 — Vol.55(2) — P.303−306.
- Namboodiri N. Electrocardiographical case. J wave and presyncope in a middle-aged woman. // Singapore Med J. 2008 Feb-49(2): 160−3.
- Nappi S, Saha H, Virtanen V, et al. Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy // Cardiology. 2000−93:229−233.
- NIH Consensus Development Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. // Ann Intern Med. 1991 — 114:593−597.
- Nilsson IL, Aberg J, Rastad J, et al. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. // Surgery. -1999−129:1049−1055.
- Nilsson IL, Aberg J, Rastad J, et al. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism — effects of parathyroidectomy. // Surgery. 2000−128:895−902.
- Nilsson H, Rastad J, Johanson K, Lind L. Endothelial vasodilatory function and blood pressure response to local and systemic hypercalcemia. // Surgery. -2001- 130(6): 986−90.
- Nilsson I.L., Yin L., Lundgren E. et al. Clinical presentation of primary hyperparathyroidism in Europe—nationwide cohort analysis on mortality from nonmalignant causes. // J Bone Miner Res. 2002- 17 Suppl 2: N68.
- Ochetta E, Bortnic M, Magnani A et al. Primary hyperparathyroidism and arrhythmic storm in a patient with an implantable cardioverter defibrillator for primary prevention of sudden death. // Europace. 2004- 6(3): 184−188.
- Ohara N, Hiramatsu K, Shigematsu S. et al. Effect of parathyroid hormone on left ventricular diastolic function in patients with primary hyperparathyroidism. // Miner Electrolyte Metab. 1995- 21(l-3):63−6.
- Ogino K, Burkhoff D, Bilezikian JP. 1995 The hemodynamic basis for the cardiac effect of parathyroid hormone and parathyroid hormone-related protein. //Endocrinology. 136:3024−3030.
- Palmer M, Adami HO, Bergstrom R, et al. Survival and renal function in untreated hypercalcemia. Population-based cohort study with 14 years of follow-up. //Lancet. 1987−10:59−62.
- Palmer M, Adami HO, Bergstrom R, Akerstrom G, Ljunghall S Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. // Surgery. 1987 — 102:1−7.,
- Palmer M, Jakobsson S, Akerstrom G, Ljunghall S Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. // Eur J Clin Invest. 1988 Feb-18(l):39−46.
- Parker C., Blackwell P., Fairbairn K., D. J. Hosking. Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study. // J Clin.Endocrinol.Metab. 2002 — 87(10) — pp.4482−9.
- Parisien M, Silverberg SJ, Shane E, De La Cruz L, Lindsay R, Bilezikian J, Dempster DW. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. // J Clin Endocrinol Metab. 1990. — 70:930 -938.
- Parisien M, Mellish RW, Silverberg SJ, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular and strut analysis. // J Bone Miner Res. 1992 — 7:913−920.
- Perna AF, Smogorzewski M, Massry SG. Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. // Kidney Int -1989−36:453−457.
- Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. // J Clin Endocrinol Metab. 2005 — 90:135−141.
- Pecherstorfer M, Brenner K, Zojer N. Current management strategies for hypercalcemia. // Treat Endocrinol. 2003- 2(4):273−92.
- Pepersack T, Jabbour N, Fuss M et al. Hyperuricemia and renal handling of urate in primary hyperparathyroidism. //Nephron. 1989−53(4): 349−52.
- Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. // Clin Endocrinol. 1999−50:321−328.
- Piecha G, Chudek J, Wiecek A. Multiple Endocrine Neoplasia type 1. // Eur J Intern Med. 2008 Mar- 19(2):99−103.
- Polyzois Makras, — Socrates E. Papapoulos Medical treatM3Ht of hypercalcaemia. //Hormones. 2009, 8(2):83−95.
- Prager R et al. Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery. // Calcified Tissue International. 1990,46: 1−4.
- Prager R et al. Peripheral insulin resistance in primary hyperparathyroidism. // Metabolism. 1983, 32: 800−805.
- Procopio M et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. // Diabetic Medicine 2002, 19: 958−961.
- Procopio M and Boretta G. Derangement of glucose metabolism in Hyperparathyroidism. // J Endocrinol Invest. 2003, 26(1): 1136−1142.
- Quin JD and Gumpert JR. Remission of non-insulin-dependent diabetes mellitus following resection of a parathyroid adenoma. // Diabetic Medicine. -1997, 14:80−81.
- Rock K, Fattah N, O’Malley D, McDermott E. The management of acute parathyroid crisis secondary to parathyroid carcinoma: a case report. // J Med Case Reports. 2010, 4:28.
- Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. // J Clin Endocrinol Metab. 1988−67:1294−8.
- Richards AM, Espiner EA, Nichols MG et al. Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. // J Hypertens. 1988- 6(9):747−52.
- Richards ML and Thompson NW. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy? // Surgery. -1999, 126: 1160−1166.
- Ringe JD. Reversible hypertension in primary hypertension in primary hyperparathyroidism pre and postoperative blood pressure in 75 cases. // Klin Wochenschr. — 1984- 62(10):465−9.
- Rodrigeuez-portales Ja, Fardella C. Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure. // J of Endocrinol Investigation. 1994- 17: 307 311.
- Rosenqvist M. Cardiac conduction in patients with hypercalcaemia due to primary hyperparathyroidism. // Clin Endocrinol (Oxf). 1992 Jul-37(l):29−33.
- Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S 2001 Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. // J Bone Miner Res. 16:113−119.
- Shetty S., Nelson M., Carpentier D., and Borker R. Description of Subjects with Primary Hyperparathyroidism. Ref Type: Report. — 2007.
- Shimoyama M, Ogino K, Furuse Y, et al. Signaling pathway and chronotropic action of parathyroid hormone in isolated perfused rat heart. // J Cardiovasc Pharmacol. 2001−38:491−499.
- Shoback DM, Bilezikian JP, Turner SA, McCaiy LC, Guo MD, Peacock M The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. // J Clin Endocrinol Metab. 2003 — 88:5644— 5649.
- Silverberg SJ, Shane E, Dempster DW & Bilezekian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. // American Journal of Medicine. 1999 107 561−567.
- Silverberg SJ. Cardiovascular disease in primary hyperparathyroidism. // J Clin Endocrino and Metabolism. 2000- Vol.85, N10: 3513−3514.
- Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. // J Clin Endocrinol Metab. 2009−94:351−365.
- Sitges Serra A. Comments on a series of 38 cases of primary hyperparathyroidism. // Med Clin (Bare) — 1981 May 10- 76(9): 381−7.
- Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. // J Clin Endocrinol and Methabolism 2000- 85(10):3515−3519.
- Smogorzewski M, Perna AF, Borum PR, et al. Fatty acid oxidation in the myocardium: effects of parathyroid hormone and CRF. // Kidney Int -1998−34:797−803.
- Stampfer MJ et al. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. // J of the American Medical Association. 1996, 276: 882−888.683.687.
- Taylor WH, Khaleeli AA. Prevalence of primary hyperparathyroidism in patients with diabetes mellitus. // Diabetic Medicine. 1997, 14: 386−389.
- The American Association of clinical endocrinologists and The American Association of endocrine surgeons. Position statement on the diagnosis and management of primary hyperparathyroidism. Endocrine practice. — Vol 11 №. 1. January/February 2005.
- Bilesikian J.P., Levine M.A. The Parathyroids, 2 edition. San Diego, Academic Press. — 2001.
- Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML. Surgical approach in hereditary hyperparathyroidism. // Endoer J. 2009−56(7):827−41.
- Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN 1). // Q J Med. 1996 — 89:653−669.
- Uchino S, Noguchi S, Sato M, et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. // Cancer Res. 2000. — 60:5553−5557.
- Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. // J Clin Endocrinol Metab. 2009−94:366−372.
- Uden P., Chan A., Duh Q.Y., Siperstein A., Clark O.H. Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery. // World J Surg. 1992 — Vol. 16(4) — P. 791−797.
- Valdemarsson S et al. Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism. // European J of Endocrinology. -1996, 134: 320−325.
- Valdemarsson S et al. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of parathyroidectomy. // J Inter Med. -1998, 244(3): 241−249.
- VanderWalde L, Liu I, O’Connell T, Haigh P. The Effect of Parathyroidectomy on Bone Fracture Risk in Patients With Primary Hyperparathyroidism. // Arch Surg.—2006 141 — PP. 885−891.
- Vaziri ND et al. Lipid fractions in primary hyperparathyroidism before and after surgical cure. // Acta Endocrinol. Copenh. — 1983, 10: 539−542.
- Vestergaard P, Mosekilde L. Incidence of primary hyperparathyroidism, frequency of surgical interventions and ortality based on the data from the National Patient Registry. Ugeskr Laeger. — 2004−166:41−5.
- Vestergaard P, Mollerup CL, Frakjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. // BMJ. -2000. Sep 9−321(7261):598−602.
- Vogel M, Hahn M, Delling G. 1995 Trabecular structure in patients with primary hyperparathyroidism. // Virchows Arch. 426:127−134.
- Voss DM and Drake EH. Cardiac manifestations of hyperparathyroidism, with presentation of a previously unreported arrhythmia. // Am Heart J. 1967- 72: 235−239.
- Weber T, Keller M, Hense I, Pietsch A, Hinz U, Schilling T et al. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism. // World J Surg. 2007−31:1202−9.
- Weisinger J.R., Bellorin-Font E. Magnesium and phosphorus. // Lancet. 1998- 352:391.
- Weimers RA, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ 3rd Incidence of primary hyperparathyroidism in Rochester, Minnesota, 19 932 001: an update on the changing epidemiology of the disease. // J Bone Miner
- Res.-2006 Jan-21(l):171−7.
- Wermers RA, Khosla S, Atkinson EJ et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. // Am J Med. 1998 104:115 122.
- Wermers R.A., Khosla S., Atkinson E.J., et al. Survival after diagnosis of PHPT: a population based study. // Am J Med. 1998 — Vol. 104 — P. 115−122.
- Yamashita AC, Ishizaki M, Nakamoto M, Kawanishi H, Hamada H. Reevaluation of adequate dose in Japanese peritoneal dialysis patients. // Adv Perit Dial.-2003−19:103−5.
- Yamashita H, Noguchi S, Uchino S, Watanabe S, Muratami T, Ogawa T, Masatsugu T, Takamatsu Y, Miyatake E, Yamashita H Influence of renal function on clinico-pathological features of primary hyperparathyroidism. // Eur J Endocrinol. 2003. — 148:597−602.
- Yamamoto S, Hiraishi K, Nakamura S, Ghazizadeh M. Serum and urinary uric acid in primary hyperparathyroidism. // Br J Urol- 1987 May- 59(5):386−9.
- Yashiro T, Hara H, Ito K et al. Pseudogout associated with primary hyperparathyroidism: management in the immediate postoperative period for prevention of acute pseudogout attack. // Endocrinol Jpn. 1988 Aug- 35(4): 617−24.
- Yashiro T, Okamoto T, Tanaka R et al. Prevalence of chondrocalcinosis in patients with primary hyperparathyroidism in Japan. // Endocrinol Jpn. 1991 Oct- 38(5): 457−64.
- Yu*, Peter T. Donnan*, Michael J. Murphyf and Graham P. LeeseJ Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. // Clinical Endocrinology. (2009) 71, 485−493.
- Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. // Surgery. 2006−140:874−881- discussion 881−882.
- Zanocco K, Sturgeon C. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. // Surgery. 2008−144:290−298.